Freeze‐dried platelets are a promising alternative in bleeding thrombocytopenic patients with hematological malignancies
dc.contributor.author | Ohanian, Maro | |
dc.contributor.author | Cancelas, Jose A. | |
dc.contributor.author | Davenport, Robertson | |
dc.contributor.author | Pullarkat, Vinod | |
dc.contributor.author | Hervig, Tor | |
dc.contributor.author | Broome, Catherine | |
dc.contributor.author | Marek, Kelly | |
dc.contributor.author | Kelly, Mary | |
dc.contributor.author | Gul, Zartash | |
dc.contributor.author | Rugg, Neeta | |
dc.contributor.author | Nestheide, Shawnagay | |
dc.contributor.author | Kinne, Bridget | |
dc.contributor.author | Szczepiorkowski, Zbigniew | |
dc.contributor.author | Kantarjian, Hagop | |
dc.contributor.author | Pehta, Joan | |
dc.contributor.author | Biehl, Ruth | |
dc.contributor.author | Yu, Anna | |
dc.contributor.author | Aung, Fleur | |
dc.contributor.author | Antebi, Ben | |
dc.contributor.author | Fitzpatrick, Glen Michael | |
dc.date.accessioned | 2022-03-07T03:13:07Z | |
dc.date.available | 2023-04-06 22:13:06 | en |
dc.date.available | 2022-03-07T03:13:07Z | |
dc.date.issued | 2022-03-01 | |
dc.identifier.citation | Ohanian, Maro; Cancelas, Jose A.; Davenport, Robertson; Pullarkat, Vinod; Hervig, Tor; Broome, Catherine; Marek, Kelly; Kelly, Mary; Gul, Zartash; Rugg, Neeta; Nestheide, Shawnagay; Kinne, Bridget; Szczepiorkowski, Zbigniew; Kantarjian, Hagop; Pehta, Joan; Biehl, Ruth; Yu, Anna; Aung, Fleur; Antebi, Ben; Fitzpatrick, Glen Michael (2022). "Freeze‐dried platelets are a promising alternative in bleeding thrombocytopenic patients with hematological malignancies." American Journal of Hematology 97(3): 256-266. | |
dc.identifier.issn | 0361-8609 | |
dc.identifier.issn | 1096-8652 | |
dc.identifier.uri | https://hdl.handle.net/2027.42/171872 | |
dc.description.abstract | Thrombosomes are trehalose‐stabilized, freeze‐dried group O platelets with a 3‐year shelf life. They can be stockpiled, rapidly reconstituted, and infused regardless of the recipient’s blood type. Thrombosomes thus represent a potential alternative platelet transfusion strategy. The present study assessed the safety and potential early signals of efficacy of Thrombosomes in bleeding thrombocytopenic patients. We performed an open‐label, phase 1 study of single doses of allogeneic Thrombosomes at three dose levels in three cohorts, each consisting of eight patients who had hematologic malignancies, thrombocytopenia, and bleeding. Adverse events, dose‐limiting toxicities (DLTs), World Health Organization (WHO) bleeding scores, and hematology values were assessed. No DLTs were reported. The median age was 59 years (24–71). Most patients had AML (58%) or ALL (29%), followed by MDS (8%) and myeloproliferative neoplasm (4%). The WHO scores of 22 patients who were actively bleeding at a total of 27 sites at baseline either improved (n = 17 [63%]) or stabilized (n = 10 [37%]) through day 6. Twenty‐four hours after infusion, 12 patients (50%) had a clinically significant platelet count increase. Of eight patients who received no platelet transfusions for 6 days after Thrombosomes infusion, 5 had a clinically significant increase in platelet count of ≥5000 platelets/μL and 2 had platelet count normalization. Thrombosomes doses up to 3.78 × 108 particles/kg demonstrated safety in 24 bleeding, thrombocytopenic patients with hematological malignancies. Thrombosomes may represent an alternative to conventional platelets to treat bleeding. A phase 2 clinical trial in a similar patient population is underway. | |
dc.publisher | John Wiley & Sons, Inc. | |
dc.title | Freeze‐dried platelets are a promising alternative in bleeding thrombocytopenic patients with hematological malignancies | |
dc.type | Article | |
dc.rights.robots | IndexNoFollow | |
dc.subject.hlbsecondlevel | Oncology and Hematology | |
dc.subject.hlbsecondlevel | Molecular, Cellular and Developmental Biology | |
dc.subject.hlbtoplevel | Science | |
dc.subject.hlbtoplevel | Health Sciences | |
dc.description.peerreviewed | Peer Reviewed | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/171872/1/ajh26403_am.pdf | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/171872/2/ajh26403.pdf | |
dc.identifier.doi | 10.1002/ajh.26403 | |
dc.identifier.source | American Journal of Hematology | |
dc.identifier.citedreference | Devine DV, Serrano K. The platelet storage lesion. Clin Lab Med. 2010; 30 ( 2 ): 475 ‐ 487. | |
dc.identifier.citedreference | Aubron C, Flint AWJ, Ozier Y, McQuilten Z. Platelet storage duration and its clinical and transfusion outcomes: a systematic review. Crit Care. 2018; 22 ( 1 ): 185. | |
dc.identifier.citedreference | Sapiano MRP, Jones JM, Savinkina AA, Haass KA, Berger JJ, Basavaraju SV. Supplemental findings of the 2017 National Blood Collection and Utilization Survey. Transfusion. 2020; 60 ( Suppl 2 ): S17 ‐ S37. | |
dc.identifier.citedreference | Wu YY, Tang L, Wang MH. Leukemia and risk of venous thromboembolism: a meta‐analysis and systematic review of 144 studies comprising 162,126 patients. Sci Rep. 2017; 7 ( 1 ): 1167. | |
dc.identifier.citedreference | LaVerda D, Shinefeld L, Best N, Lisitu J, Tambolleo G, Vallejo YR. Evaluation of an improved rapid bacterial assay with untreated and pathogen‐reduced platelets: Detection of Acinetobacter strains. Transfusion. 2021; 61 ( 9 ): 2710 ‐ 2717. | |
dc.identifier.citedreference | FDA. Bacterial risk control strategies for blood collection establishments and transfusion services to enhance the safety and availability of platelets for transfusion. Vol. 2021; 2021. | |
dc.identifier.citedreference | USP. Sterility tests. Vol. 2021; 2016. | |
dc.identifier.citedreference | Levy JH, Neal MD, Herman JH. Bacterial contamination of platelets for transfusion: strategies for prevention. Crit Care. 2018; 22 ( 1 ): 271. | |
dc.identifier.citedreference | Toy P, Lowell C. TRALI—definition, mechanisms, incidence and clinical relevance. Best Pract Res Clin Anaesthesiol. 2007; 21 ( 2 ): 183 ‐ 193. | |
dc.identifier.citedreference | Kopko PM, Holland PV. Transfusion‐related acute lung injury. Br J Haematol. 1999; 105 ( 2 ): 322 ‐ 329. | |
dc.identifier.citedreference | Toy P, Gajic O, Bacchetti P, et al. Transfusion‐related acute lung injury: incidence and risk factors. Blood. 2012; 119 ( 7 ): 1757 ‐ 1767. | |
dc.identifier.citedreference | Milford EM, Reade MC. Comprehensive review of platelet storage methods for use in the treatment of active hemorrhage. Transfusion. 2016; 56 ( Suppl 2 ): S140 ‐ S148. | |
dc.identifier.citedreference | Goggs R, Brainard BM, LeVine DN, et al. Lyophilized platelets versus cryopreserved platelets for management of bleeding in thrombocytopenic dogs: a multicenter randomized clinical trial. J Vet Intern Med. 2020; 34 ( 6 ): 2384 ‐ 2397. | |
dc.identifier.citedreference | Triulzi DJ, Assmann SF, Strauss RG, et al. The impact of platelet transfusion characteristics on posttransfusion platelet increments and clinical bleeding in patients with hypoproliferative thrombocytopenia. Blood. 2012; 119 ( 23 ): 5553 ‐ 5562. | |
dc.identifier.citedreference | Trivedi A, Potter DR, Miyazawa BY, et al. Freeze dried platelets promote clot formation, rescue thrombin induced endothelial cell permeability, and decrease pulmonary vascular leak in a murine model of hemorrhagic shock. J Trauma Acute Care Surg. 2020; 90: 203 ‐ 214. | |
dc.identifier.citedreference | Fitzpatrick G, Vibhudatta A, Agashe H, Phillips W, Goins B, Dee J, Cliff R. Trehalose stabilized freeze dried human platelets, thrombosomes, persist in circulation 24 hours after infusion and are non‐immunogenic in new zealand white rabbits. Vox Sanguinis. 2010; 99 ( Suppl. 1 ): 262. https://onlinelibrary.wiley.com/doi/epdf/10.1111/j.1423-0410.2010.01343_2.x | |
dc.identifier.citedreference | Jones JM, Sapiano MRP, Savinkina AA, et al. Slowing decline in blood collection and transfusion in the United States—2017. Transfusion. 2020; 60 ( Suppl 2 ): S1 ‐ S9. | |
dc.identifier.citedreference | Fitzpatrick GM, Cliff R, Tandon N. Thrombosomes: a platelet‐derived hemostatic agent for control of noncompressible hemorrhage. Transfusion. 2013; 53 ( Suppl 1 ): 100S ‐ 106S. | |
dc.identifier.citedreference | Barroso J, Osborne B, Teramura G, et al. Safety evaluation of a lyophilized platelet‐derived hemostatic product. Transfusion. 2018; 58 ( 12 ): 2969 ‐ 2977. | |
dc.identifier.citedreference | American Red Cross. Critical blood shortage: Red Cross urges blood and platelet donors to give now; 2020. | |
dc.identifier.citedreference | Mulcahy A, Kapinos K, Briscombe B, et al. Toward a sustainable blood supply in the United States: an analysis of the current system and alternatives for the future. RAND Corporation; 2016. | |
dc.identifier.citedreference | U.S. Food and Drug Administration. Coronavirus (COVID‐19) update: blood dnations; 2020. | |
dc.identifier.citedreference | Klein HG, Hrouda JC, Epstein JS. Crisis in the sustainability of the U.S. blood system. N Engl J Med. 2017; 377 ( 15 ): 1485 ‐ 1488. | |
dc.identifier.citedreference | Refaai MA, Phipps RP, Spinelli SL, Blumberg N. Platelet transfusions: impact on hemostasis, thrombosis, inflammation and clinical outcomes. Thromb Res. 2011; 127 ( 4 ): 287 ‐ 291. | |
dc.identifier.citedreference | Delaney M, Wendel S, Bercovitz RS, et al. Transfusion reactions: prevention, diagnosis, and treatment. Lancet. 2016; 388 ( 10061 ): 2825 ‐ 2836. | |
dc.identifier.citedreference | Haass KA, Sapiano MRP, Savinkina A, Kuehnert MJ, Basavaraju SV. Transfusion‐transmitted infections reported to the national healthcare safety network hemovigilance module. Transfus Med Rev. 2019; 33 ( 2 ): 84 ‐ 91. | |
dc.identifier.citedreference | Jones SA, Jones JM, Leung V, et al. Sepsis attributed to bacterial contamination of platelets associated with a potential common source—multiple states, 2018. MMWR Morb Mortal Wkly Rep. 2019; 68 ( 23 ): 519 ‐ 523. | |
dc.working.doi | NO | en |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.